Kunming Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kunming China (1933)

Organization Overview

First Clinical Trial
2008
NCT00703742
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

First Affiliated Hospital of Kunming Medical College | First People's Hospital of Kunming | Kunming Children's Hospital | Kunming Medical University | Kunming Yan'an Hospital | Psychiatry Department ,First Affiliated Hospital Of Kunming Medical University | The First Affiliated Hospital of Kunming Medical College | The Second Affiliated Hospital of Kunming Medical University | The Third Affiliated Hospital of Kunming Medical College. | The Third Affiliated Hospital of Kunming Medical University | The Third Affiliated Hospital of Kunming Medicine University | The Third People's Hospital of Kunming | The Third People's Hospital of Kunming City | The Third People's Hospital of Kunshan | Yan'an Affiliated Hospital of Kunming Medical University | YuNan Province Tumor Hospital | Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center | Yuqi Cheng

Active Ingredients

Drugs in Phase 4 Trials (17)

aminolevulinic acid (levulan) (1 trial)

bupropion (wellbutrin) (2 trials)

eltrombopag (promacta) (1 trial)

ethambutol (myambutol) (1 trial)

fluoxetine (prozac) (1 trial)

fluvoxamine (luvox) (2 trials)

insulin human (humulin) (1 trial)

interferon alpha-2b (Intron-A) (3 trials)

isoniazid (nydrazid) (1 trial)

levofloxacin (levaquin) (1 trial)

lithium (lithonate) (1 trial)

mirtazapine (remeron) (1 trial)

olanzapine (zyprexa) (1 trial)

pyrazinamide (Aldinamide) (1 trial)

rifampin (1 trial)

rituximab (rituxan) (2 trials)

somatropin (protropin) (1 trial)

Drugs in Phase 3 Trials (27)

aclarubicin (2 trials)

capecitabine (xeloda) (2 trials)

cetuximab (erbitux) (1 trial)

ciltacabtagene autoleucel (Carvykti) (1 trial)

cisplatin (platinol) (2 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

cytarabine (cytosar-u) (2 trials)

decitabine (dacogen) (2 trials)

dexamethasone (1 trial)

epirubicin (ellence) (1 trial)

Filgrastim (neupogen) (2 trials)

fluorouracil (efudex) (2 trials)

idarubicin (idamycin) (1 trial)

irinotecan (Camptosar) (1 trial)

lenalidomide (revlimid) (1 trial)

leucovorin (2 trials)

methylprednisolone (medrol) (1 trial)

naproxen (naprosyn) (1 trial)

omacetaxine (synribo) (2 trials)

oxaliplatin (eloxatin) (2 trials)

somatostatin (1 trial)

sumatriptan (zecuity) (1 trial)

tamoxifen (nolvadex) (1 trial)

toremifene (fareston) (1 trial)

ursodeoxycholic acid (1 trial)

Ursodoxicoltaurine (1 trial)

Drugs in Phase 2 Trials (16)

aripiprazole (abilify) (1 trial)

autologous cytokine induced killer cells (1 trial)

autologous lung cancer specific T cells (1 trial)

avatrombopag (1 trial)

cervical cancer specific engineered immune effectors (1 trial)

cord blood hematopoietic stem cell (1 trial)

erlotinib (tarceva) (1 trial)

gefitinib (iressa) (1 trial)

hetrombopag olamine (1 trial)

lapatinib (tykerb) (1 trial)

memantine (namenda) (1 trial)

oc-eies (1 trial)

ovarian cancer specific cytotoxic lymphocytes (1 trial)

sertraline (zoloft) (1 trial)

umbilical cord mesenchymal stem cells (3 trials)

venlafaxine (effexor) (1 trial)

Drugs in Phase 1 Trials (8)

amniotic stem cells (1 trial)

anti-cd19 fast car-t cells (1 trial)

cd19 car-t cells (3 trials)

cd7 car-t cell (1 trial)

duloxetine (Cymbalta) (1 trial)

escitalopram (lexapro) (2 trials)

fludarabine (fludara) (2 trials)

melphalan (alkeran) (2 trials)

Drugs in Other Trials (9)

azathioprine (imuran) (1 trial)

dexmedetomidine (precedex) (1 trial)

heparin (liquaemin) (1 trial)

leflunomide (arava) (1 trial)

lopinavir (Kaletra) (1 trial)

phenylephrine (Prefrin) (1 trial)

remifentanil (ultiva) (1 trial)

ropivacaine (naropin) (1 trial)

uropidil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Breast Neoplasms (Phase 3)

Burns (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Cholestasis (Phase 3)

Communicable Diseases (Phase 2)

Compulsive Personality Disorder (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetic Nephropathies (Phase 1)

Disease (Phase 4)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Gallbladder Neoplasms (Phase 3)

Hemophilia A (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hypertriglyceridemia (Phase 4)

Infections (Phase 2)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Kidney Diseases (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, T-Cell (Phase 1)

Liver Diseases (Phase 3)

Lung Neoplasms (Phase 2)

Lupus Nephritis (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 3)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Nasopharyngeal Carcinoma (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Neoplasms, Second Primary (Phase 3)

Nephritis (Phase 1)

Obsessive-Compulsive Disorder (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatitis (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Schizophrenia (Phase 4)

Thrombocytopenia (Phase 4)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 77